Author:
Lapucci Caterina,Baroncini Damiano,Cellerino Maria,Boffa Giacomo,Callegari Ilaria,Pardini Matteo,Novi Giovanni,Sormani Maria Pia,Mancardi Giovanni Luigi,Ghezzi Angelo,Zaffaroni Mauro,Uccelli Antonio,Inglese Matilde,Roccatagliata Luca
Abstract
ObjectiveTo analyze MRI images in patients with MS who experienced worsening of neurologic status (WNS) after stopping fingolimod (FTY).MethodsIn this retrospective study, demographic, clinical, and radiologic data of patients with MS who experienced WNS after stopping FTY were retrospectively collected. We introduced the “δExpanded Disability Status Scale (EDSS)-ratio” to identify patients who, after FTY withdrawal, showed an inflammatory flare-up exceeding the highest lifetime disease activity level. Patients with δEDSS-ratio > 1 were enrolled in the study.ResultsEight patients were identified. The mean (SD) age of the 8 (7 female) patients was 35.3 (4.9) years. The mean FTY treatment duration was 3.1 (0.8) years. The mean FTY discontinuation–WNS interval was 4 (0.9) months. The 4 patients with δEDSS-ratio ≥ 2 developed severe monophasic WNS (EDSS score above 8.5), characterized by clinical features and MRI findings not typical of MS, which we classified as “tumefactive demyelination pattern” (TDL) and “Punctuated pattern” (PL). Conversely, patients whose δEDSS-ratio was between 1 and 2 had clinical features and brain MRI compatible with a more typical, even if aggressive, MS relapse. In patients with TDL and PL, the flare-up of inflammatory activity led to severe tissue damage resulting in T2 but also T1 lesion volume increase at 6-month follow-up.ConclusionsPeculiar MRI features (TDL and PL), different from a typical MS flare-up, might occur in some patients who experienced WNS after stopping FTY. Further studies, also involving immunologic biomarkers, are necessary to investigate TDL or PL pathophysiology.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Clinical Neurology,Neurology
Reference11 articles.
1. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment;Hatcher;JAMA,2016
2. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation;Berger;J Neuroimmunol,2015
3. Rebound of Disease Activity After Withdrawal of Fingolimod (FTY720) Treatment
4. FDA. Gilenya (Fingolimod): Drug Safety Communication-Severe Worsening of Multiple Sclerosis After Stopping the Medicine. 2018. Available at: fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm626264.htm. Accessed November 21, 2018.
5. A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo;Vermersch;Mult Scler J Exp Transl Clin,2017
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献